keyword
MENU ▼
Read by QxMD icon Read
search

BCG immunotherapy

keyword
https://www.readbyqxmd.com/read/29286018/miliary-pulmonary-infection-after-bcg-intravesical-instillation-a-rare-misdiagnosed-and-mistreated-complication
#1
Giorgio Calleris, Giancarlo Marra, Silvia Corcione, Marco Oderda, Chiara Cardellino, Sabrina Audagnotto, Bruno Frea, Francesco Giuseppe De Rosa, Paolo Gontero
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy decreases the progression risk of non-muscle-invasive bladder cancer, but potentially yields a broad spectrum of side effects. We report the case of a 73-year-old man affected by miliary pulmonary BCG infection, whose microbiological diagnosis was probably hindered by empiric fluoroquinolones, focusing on imaging and clinical work-up.
December 1, 2017: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/29273406/re-radical-cystectomy-bladder-removal-against-intravesical-bcg-immunotherapy-for-high-risk-non-muscle-invasive-bladder-cancer-bravo-a-protocol-for-a-randomised-controlled-feasibility-study
#2
https://www.readbyqxmd.com/read/29247502/immunotherapy-excluding-checkpoint-inhibitors-for-stage-i-to-iii-non-small-cell-lung-cancer-treated-with-surgery-or-radiotherapy-with-curative-intent
#3
REVIEW
Jianwei Zhu, Rui Li, Eva Tiselius, Raheleh Roudi, Olivia Teghararian, Chen Suo, Huan Song
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For patients with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. While several new agents have now entered phase III clinical trials, we felt a systematic review was needed to address the question of the effectiveness and safety of immunotherapy in patients with stages I to III NSCLC...
December 16, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29205200/immunotherapy-in-metastatic-urothelial-carcinoma-focus-on-immune-checkpoint-inhibition
#4
REVIEW
Arlene Siefker-Radtke, Brendan Curti
Immunotherapy has been used in localized urothelial carcinoma for decades, especially in the treatment of superficial disease, in which instillation of BCG is a commonly used treatment option. Clinical investigations based on new insights into the immunogenic potential of metastatic urothelial carcinoma have led to the accelerated FDA approval of the immune checkpoint inhibitors atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab. Preliminary findings suggest additional benefits of combinations of immunotherapeutic agents as a future treatment approach in metastatic urothelial carcinoma...
December 5, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29201501/alternative-therapies-in-patients-with-non-muscle-invasive-bladder-cancer
#5
REVIEW
Öner Şanlı, Yair Lotan
Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required...
December 2017: Turkish Journal of Urology
https://www.readbyqxmd.com/read/29179475/genetic-variants-in-the-inflammation-pathway-as-predictors-of-recurrence-and-progression-in-non-muscle-invasive-bladder-cancer-treated-with-bacillus-calmette-gu%C3%A3-rin
#6
Stephen B Williams, Ashish M Kamat, Chinedu Mmeje, Yuanquing Ye, Maosheng Huang, David W Chang, Colin P Dinney, Xifeng Wu
Inflammation plays a critical role in the etiology of several cancers and may affect their clinical outcome. Our objective was to assess the association of genetic variants within the inflammation pathway with recurrence and progression among non-muscle invasive bladder cancer (NMIBC) patients with or without Bacillus Calmette-Guérin (BCG) treatment. We genotyped 372 single nucleotide polymorphisms (SNPs) in 27 selected genes within the inflammation pathway in 349 patients diagnosed with NMIBC, followed by internal validation in 322 additional patients...
October 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152556/bladder-sparing-therapy-for-bcg-failures-i-intravesical-immunotherapy
#7
Edward M Messing
No abstract text is available yet for this article.
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29145329/new-onset-of-myasthenia-gravis-after-intravesical-bacillus-calmette-guerin-a-case-report-and-literature-review
#8
Tsubasa Takizawa, Marenori Kojima, Shigeaki Suzuki, Takashi Osada, Satoshi Kitagawa, Jin Nakahara, Shinichi Takahashi, Norihiro Suzuki
RATIONALE: Recently, drug-related myasthenia gravis (MG) has received attention, because the number of reported cases involving MG associated with immune checkpoint inhibitors, a new immunotherapy, is increasing. We present a case involving the new onset of MG, in which the symptoms started shortly after intravesical Bacillus Calmette-Guerin (BCG) for bladder cancer. PATIENT CONCERNS: A 69-year-old male with bladder cancer developed ptosis and diplopia 4 days after the completion of a treatment regimen with intravesical BCG weekly for 6 weeks...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29081034/primary-high-grade-non-muscle-invasive-bladder-cancer-high-nf%C3%AE%C2%BAb-expression-in-tumor-specimens-distinguishes-patients-who-are-at-risk-for-disease-progression
#9
Lampros Mitrakas, Stavros Gravas, Christos Papandreou, Georgios Koukoulis, Foteini Karasavvidou, Georgios Dimakopoulos, Karl Weingärtner, Anastasios Karatzas, Ioannis Zachos, Vasilios Tzortzis
To investigate the potential prognostic role of NFκB expression in primary high-grade non-muscle-invasive bladder cancer. Patients with primary high-grade non-muscle-invasive bladder cancer who received induction and maintenance BCG therapy were retrospectively included. Recurrence and progression were histologically proven. Intensity and extent of immunochemistry were assessed. The final evaluation of the NFκB staining was done by combining intensity and extent as ΄΄product΄΄ and expressing it as ΄΄low NFκΒ expression΄΄ or ΄΄high NFκB expression΄΄...
October 28, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29055653/predicting-response-to-intravesical-bacillus-calmette-gu%C3%A3-rin-immunotherapy-are-we-there-yet-a-systematic-review
#10
REVIEW
Ashish M Kamat, Roger Li, Michael A O'Donnell, Peter C Black, Morgan Roupret, James W Catto, Eva Comperat, Molly A Ingersoll, Wim P Witjes, David J McConkey, J Alfred Witjes
CONTEXT: Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also preventing progression and reducing deaths. However, response rates to BCG vary widely and are dependent on a multitude of factors. OBJECTIVE: To review existing data on clinical, pathologic, immune, and molecular markers that allow prediction of BCG response. EVIDENCE ACQUISITION: PubMed and MEDLINE search of English language literature was conducted from its inception to July 2017 using appropriate search terms...
October 18, 2017: European Urology
https://www.readbyqxmd.com/read/29029943/bcg-immune-activation-reduces-growth-and-angiogenesis-in-an-in-vitro-model-of-head-and-neck-squamous-cell-carcinoma
#11
Carolina Sánchez-Rodríguez, Keyliz Peraza Cruces, Juan Riestra Ayora, Eduardo Martín-Sanz, Ricardo Sanz-Fernández
Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent cancers worldwide and is associated with poor survival and significant treatment morbidity. The immune profile in patients with HNSCC is immunosuppressive and presents cytokine-mediated adaptive immune responses, triggered apoptosis of T cells, and alterations in antigen processing machinery. Bacille Calmette-Guerin (BCG) immunotherapy has been used successfully as a treatment for several types of cancer. In the present study, we sought to determine the antitumor effect of soluble mediators from peripheral blood mononuclear immune cells (PBMCs) activated with BCG vaccine in a three-dimensional coculture model of HNSCC growth using FaDu hypopharynx carcinoma squamous cells...
November 7, 2017: Vaccine
https://www.readbyqxmd.com/read/29026546/systemic-bcg-osis-following-intravesical-bcg-instillation-for-bladder-carcinoma
#12
Frank Liaw, Yan Yu Tan, David Hendry
Intravesical instillation of Bacillus Calmette-Guérin (BCG) has been shown to be an effective form of immunotherapy for bladder cancer. This case report describes a patient who develops systemic BCG-osis following intravesical BCG instillation and demonstrates the importance of being aware of more severe complications associated with BCG immunotherapy.
October 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/29019177/long-term-survival-after-complete-surgical-resection-and-adjuvant-immunotherapy-for-distant-melanoma-metastases
#13
Mark B Faries, Nicola Mozzillo, Mohammed Kashani-Sabet, John F Thompson, Mark C Kelley, Ronald C DeConti, Jeffrey E Lee, James F Huth, Jeffrey Wagner, Angus Dalgleish, Daniel Pertschuk, Christopher Nardo, Stacey Stern, Robert Elashoff, Guy Gammon, Donald L Morton
BACKGROUND: This phase III study was undertaken to evaluate the efficacy of an allogeneic whole-cell vaccine (Canvaxin™) plus bacillus Calmette-Guerin (BCG) after complete resection of stage IV melanoma. METHODS: After complete resection of ≤5 distant metastases, patients were randomly assigned to BCG+Canvaxin (BCG/Cv) or BCG+placebo (BCG/Pl). The primary endpoint was overall survival (OS); secondary endpoints were disease-free survival (DFS), and immune response measured by skin test (ClinicalTrials...
October 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28931051/interleukin-17-positive-mast-cells-influence-outcomes-from-bcg-for-patients-with-cis-data-from-a-comprehensive-characterisation-of-the-immune-microenvironment-of-urothelial-bladder-cancer
#14
Alexander C Dowell, Ellen Cobby, Kaisheng Wen, Adam J Devall, Vinnie During, Jane Anderson, Nicholas D James, Kar K Cheng, Maurice P Zeegers, Richard T Bryan, Graham S Taylor
The tumour immune microenvironment is considered to influence cancer behaviour and outcome. Using a panel of markers for innate and adaptive immune cells we set out to characterise and understand the bladder tumour microenvironment of 114 patients from a prospective multicentre cohort of newly-diagnosed bladder cancer patients, followed-up for 4.33±1.71 years. We found IL-17-positive cells were significantly increased in primary and concomitant carcinoma in situ (CIS), p<0.0001, a highly malignant lesion which is the most significant single risk factor for disease progression...
2017: PloS One
https://www.readbyqxmd.com/read/28916862/monitoring-the-response-of-urothelial-precancerous-lesions-to-bacillus-calmette-guerin-at-the-proteome-level-in-an-in-vivo-rat-model
#15
Kerem Teke, Nil Guzel, Ali Kemal Uslubas, Murat Kasap, Hasan Yilmaz, Gurler Akpinar, Demir Kursat Yildiz, Ozdal Dillioglugil
Intravesical Bacillus Calmette-Guerin (BCG) is the best treatment modality for progression of non-muscle invasive bladder cancer. We aimed to monitor changes at the proteome level to identify putative protein biomarkers associated with the response of urothelial precancerous lesions to intravesical BCG treatment. The rats were divided into three groups (n = 10/group): control, non-treated, and BCG-treated groups. The non-treated and BCG-treated groups received N-methyl-N-nitrosourea intravesically. BCG Tice-strain was instilled into bladder in BCG-treated group...
September 15, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28903359/expression-of-sialyl-tn-sugar-antigen-in-bladder-cancer-cells-affects-response-to-bacillus-calmette-gu%C3%A3-rin-bcg-and-to-oxidative-damage
#16
Paulo F Severino, Mariana Silva, Mylene Carrascal, Nadia Malagolini, Mariella Chiricolo, Giulia Venturi, Annalisa Astolfi, Mariangela Catera, Paula A Videira, Fabio Dall'Olio
The sialyl-Tn (sTn) antigen is an O-linked carbohydrate chain aberrantly expressed in bladder cancer (BC), whose biosynthesis is mainly controlled by the sialyltransferase ST6GALNAC1. Treatment with Bacillus Calmette-Guérin (BCG) is the most effective adjuvant immunotherapy for superficial BC but one third of the patients fail to respond. A poorly understood correlation between the expression of sTn and BC patient's response to BCG was previously observed. By analyzing tumor tissues, we showed that patients with high ST6GALNAC1 and IL-6 mRNA expression were BCG responders...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902383/-bcgitis-with-involvement-of-lung-liver-and-bone-marrow%C3%A2-after-immunotherapy-of-urothelial-cancer
#17
Hilte Friederike Geerdes-Fenge, Franziska Stubbe, Micha Löbermann, Philipp Warnke, Andreas Erbersdobler, Emil Christian Reisinger
Medical history A 77-year-old patient with transurethral resection of a bladder tumor was transferred due to persistent fever and progressive dyspnea despite antibiotic therapy for suspected urinary tract infection. Repeating the medical history revealed that a BCG immunotherapy of his non-muscle-invasive bladder carcinoma was performed the day before fever developed. Therefore, BCGitis was suspected. Examinations Laboratory parameters showed pancytopenia, elevated liver enzymes, eleveated C-reactive protein and hypoxemia...
September 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28866819/fluorescence-in-situ-hybridization-as-prognostic-predictor-of-tumor-recurrence-during-treatment-with-bacillus-calmette-gu%C3%A3-rin-therapy-for-intermediate-and-high-risk-non-muscle-invasive-bladder-cancer
#18
Esmee I M L Liem, Joyce Baard, Evelyne C C Cauberg, Mieke T J Bus, D Martijn de Bruin, M Pilar Laguna Pes, Jean J M C H de la Rosette, Theo M de Reijke
A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette-Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®) is a multitarget fluorescence in situ hybridization (FISH) test for bladder cancer detection. The aim of this study was to evaluate whether FISH can be used to early identify recurrence during treatment with BCG...
September 2, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28815048/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#19
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28807024/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#20
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression...
August 15, 2017: Journal for Immunotherapy of Cancer
keyword
keyword
7100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"